Cholecystokinin's role in regulation of colonic motility in health and in irritable bowel syndrome

Niederau, Claus; Faber, S.R.; Karaus, M.

doi:10.1016/0016-5085(92)90310-u

Cited by 79 publications

(30 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…), showed that the drug signifi cantly increased the number of pain free days, improved global well being and tended to normalize bowel function in female C-IBS patients [87] . In contrast, in a clinical pharmacology study by Niederau et al [88] intravenous loxiglumide failed to inhibit the gastrocolonic response to a regular meal both in healthy volunteers and in patients with IBS syndrome. Loxiglumide also failed to alter the interdigestive colonic motor activity in the left side of the colon suggesting that the predominant action of CCK was in the ascending colon.…”

Section: Functional Gastrointestinal Disorders (Dyspepsia Irritable mentioning

confidence: 68%

CCK<sub>1</sub> Antagonists: Are They Ready for Clinical Use?

Peter

D’Amato²,

Beglinger

2006

Dig Dis

View full text Add to dashboard Cite

Cholecystokinin (CCK) is a peptide hormone which is found both in the gastrointestinal tract throughout the human small intestine and nerves in the myenteric plexus of the enteric nervous system and in the central nervous system. This dual location constitutes the anatomical basis for this in functions as a hormone and a neurotransmitter implicated in the regulation of both systems. CCK regulates not only motor functions in the gastrointestinal tract like lower oesophageal sphincter relaxation, gastric secretion and emptying, gall bladder contractility and bile secretion into the duodenum, intestinal and colonic motility, but also sensory functions and plays a role in the regulation of food intake. These effects are mediated through selective receptors CCK₁ and CCK₂. Over the last few years, research has focused on understanding the role of CCK, its receptors with antagonists at the biological, pharmacological, clinical and therapeutic level. As far as the CCK₁ antagonists is concerned, important inroads have been made in the potential role of these antagonists in the treatment of GERD, IBS and pancreatitis. They have also shown encouraging results in sphincter of Oddi dysfunction and some gastrointestinal cancers. This review focuses on the recent ad vances of the biological role of CCK and their CCK₁ antagonists: their current basic and clinical status in gastroenterology, with particular emphasis on the potential therapeutic role of the CCK₁ antagonists and future research directions.

show abstract

Section: Functional Gastrointestinal Disorders (Dyspepsia Irritable mentioning

confidence: 68%

CCK<sub>1</sub> Antagonists: Are They Ready for Clinical Use?

Peter

D’Amato²,

Beglinger

2006

Dig Dis

View full text Add to dashboard Cite

show abstract

“…Recent clinical and experimental studies have indicated the possible involvement of endogenous CCK in pancreatic and gastrointestinal physiology and pathophysiology (Meyer et al, 1989;Rovati, 1991;Schmidt et al, 1991;Beglinger et al, 1992a,b;Niederau et al, 1992;Tani et al, 1993;Herrington & 1 Author for correspondence. Adrian, 1995).…”

Section: Introductionmentioning

confidence: 99%

“…However, further studies using other CCKA receptor antagonists may be helpful in elucidating the physiological role of CCK. Thus, the development of CCKA receptor antagonists with higher selectivity for CCKA versus CCKB receptors or -with different characteristics is desirable in order to investigate new insights into digestive physiology and pathophysiology, to distinguish further CCK receptor substypes, and to examine the role of CCK in the treatment of gastrointestinal disorders (Meyer et al, 1989;Beglinger et al, 1991;1992a;Rovati, 1991;Schmidt et al, 1991;Niederau et al, 1992;Tani et al, 1993;Herrington & Adrian, 1995).…”

Section: Introductionmentioning

confidence: 99%

Pharmacological profile of TP‐680, a new cholecystokinin_A receptor antagonist

Akiyama

Tachibana

Hirohata

et al. 1996

British J Pharmacology

View full text Add to dashboard Cite

1 The pharmacological characteristics of a newly developed serine derivative (R)-1- [3-(3-carboxypyr-idine-2-yl)thio-2-(indol-2-yl)carbonylamino]propionyl-4-diphenylmethyl-piperazine suppressed the maximal responses of CCK-8-induced amylase release in a concentration-dependent fashion, indicating that TP-680 is an unsurmountable antagonist. 5Repeated washing of acini after a 30 min treatment with TP-680 restored the responsiveness but not the sensitivity, causing a residual inhibition on the action of CCK-8. 6 The addition of loxiglumide prior to or together with application of TP-680 protected CCK receptors from unsurmountable and irreversible antagonism by Our results indicate that TP-680 is a potent and the most selective CCKA receptor antagonist for the pancreas reported to date.

show abstract

“…76 Colonic myoelectrical and manometric studies have consistently reported an exaggerated colonic response to eating in IBS patients, which is more prolonged than normal. [77][78][79] Many IBS patients relate their symptoms to stress. The response of colonic motility to stress has been widely studied in animals and humans.…”

Section: Abnormal Colonic Motility Patternsmentioning

confidence: 99%

Alterations of sensori-motor functions of the digestive tract in the pathophysiology of irritable bowel syndrome

Delvaux¹

2004

Best Practice & Research Clinical Gastroenterology

View full text Add to dashboard Cite

Cholecystokinin's role in regulation of colonic motility in health and in irritable bowel syndrome

Cited by 79 publications

References 28 publications

CCK<sub>1</sub> Antagonists: Are They Ready for Clinical Use?

CCK<sub>1</sub> Antagonists: Are They Ready for Clinical Use?

Pharmacological profile of TP‐680, a new cholecystokinin_A receptor antagonist

Alterations of sensori-motor functions of the digestive tract in the pathophysiology of irritable bowel syndrome

Contact Info

Product

Resources

About

Cholecystokinin's role in regulation of colonic motility in health and in irritable bowel syndrome

Cited by 79 publications

References 28 publications

CCK<sub>1</sub> Antagonists: Are They Ready for Clinical Use?

CCK<sub>1</sub> Antagonists: Are They Ready for Clinical Use?

Pharmacological profile of TP‐680, a new cholecystokininA receptor antagonist

Alterations of sensori-motor functions of the digestive tract in the pathophysiology of irritable bowel syndrome

Contact Info

Product

Resources

About

Pharmacological profile of TP‐680, a new cholecystokinin_A receptor antagonist